Non-myeloablative (MA) and reduced intensity allo-SCT regimens are offered to older patients and/or those with comorbidities because the morbidity and mortality attributable to fully MA conditioning is thought to be unacceptably high. A total of 207 patients aged 50-66 years were treated between 1999 and 2008 with SCT after MA conditioning with fludarabine 50 mg/m 2 daily Â 5 and i.v. BU 3.2 mg/kg daily Â 4.90 (43%) had additional TBI 200 cGy Â 2. GVHD prophylaxis was CsA, MTX and thymoglobulin (4.5 mg/kg total dose). As defined by the hematopoietic cell transplantation co-morbidity index (HCT-CI) scoring system 117 (57%) pts scored 0 and 90 (43%) X1. At 5 years OS was 39 vs 54% (P ¼ 0.008), disease-free survival 38 vs 49% (P ¼ 0.03), TRM 39 vs 19% (P ¼ 0.003) and relapse 36 vs 39% (P ¼ ns) in those with scores of 0 and X1, respectively. Multivariate analysis confirmed the influence of HCT-CI scores on TRM (subhazard ratios ¼ 2.29; 95% confidence interval ¼ 1.29-4.08; P ¼ 0.005). We conclude that comorbidities as assessed by the HCT-CI do influence TRM with this regimen but that age alone should not be an indication to prefer a less intense protocol.
Introduction
Comorbidity scales have been specifically developed for SCT as tools for predicting TRM. The hematopoietic cell transplantation co-morbidity index (HCT-CI) described by Sorror et al. has shown good correlation between increasing numbers of specific comorbidities and higher TRM of patients receiving a variety of conditioning protocols. 1, 2 As the TRM of myeloablative (MA) regimens also increases with age many centers impose an upper age limit for their use, commonly 50-55 years. Older patients, and those with comorbidities, are offered non-MA (NST) or reduced intensity (RIC) regimens because the toxicity of MA protocols is felt to be unacceptably high for these individuals. [3] [4] [5] Despite extensive experience with NST and RIC regimens, their role in the management of patients with hematologic malignancy remains controversial. There is little question that reducing regimen intensity increases relapse in conditions such as AML. [6] [7] [8] [9] [10] Although this may be compensated for by a reduction in early TRM, there is some evidence that TRM of MA, RIC and NST regimens may not differ greatly at the 5-year mark.
In the last decade, a combination of i.v. BU and fludarabine, and antithymocyte globulin, with or without additional TBI, has been developed as a relatively well tolerated alternative MA regimen. [11] [12] [13] In our institution this FLUBUP regimen has been offered to virtually all patients up to 66 years old.
This study analyzes the outcomes of those patients aged 50 years and older with particular respect to the presence of comorbidities assessed by the HCT-CI. The first objective was to establish whether the HCT-CI index has predictive value in this population treated with the FLUBUP regimen. The second aim was to determine whether older age, with or without comorbidities, is sufficient to justify a preference for NST or RIC regimens for these patients.
Patients and methods

Patients
This study is a retrospective analysis of outcomes of 207 consecutive adults with hematologic malignancy treated with the FLUBUP regimen followed by a first SCT between May 1999 and August 2008. Diagnosis and other details of the patients are recorded in Table 1 . Patients in second CR are included in the low-risk group as outcomes including TRM are similar to those for CR1 patients with this regimen.
Over the study period seven additional patients received allo-SCT for hematologic malignancy. In one case NST conditioning was used because of poor performance status; in a second case an RIC protocol was given to a patient with cirrhosis. The others received alternative regimens because of previous autotransplant with FLUBUP (2) , severe Ara-C neurotoxicity (1), hepatotoxicity after a BU test dose (1) and physician preference because of underlying disease (1) .
The Institutional Review Board approved the protocol, outcome analysis and informed consent forms which all patients signed.
Comorbidity scoring
Comorbidities were documented by retrospective chart review of clinical history and pretransplant screening tests, which included pulmonary function testing on all patients. The hematopoietic cell transplantation-specific comorbidity index proposed by the Seattle group in 2005 was used to assign a comorbidity score to each patient. 1 In this system each comorbidity is given a wt of 1-3 and the sum of these is the individual patient score. Patients are then given an index of score 0 (no comorbidities), 1-2 or X3. In the current study transplant risk factors were similar between score 1-2 (n ¼ 68) and X3 HCT-CI score groups (n ¼ 22). As the latter group was so small and a preliminary univariate and multivariate analysis showed no difference in outcome between these groups, for a more robust analysis patients were divided into two groups, those with comorbidities defined by the HCT-CI (score X1) and those without (score 0) ( Table 1 ).
Treatment
The preparative chemotherapy comprised fludarabine 50 mg/m 2 on days À6 to -2 and i.v. BU (Busulfex, Otsuka Pharma, Montreal, QC, Canada) 3.2 mg/kg daily on days À5 to À2, inclusive. A total of 90 patients had additional TBI 200 cGy Â 2 on day À1 or 0.
Supportive care was similar for all patients. No protective isolation was used.
14 Single donor platelets were given to maintain counts 410 Â 10 9 /L and red cells to keep Hb levels 480g/L. Growth factors were not given routinely. All patients received twice weekly trimethoprim/sulfamethoxazole as prophylaxis for P. jirovecii. Antibacterial prophylaxis was ciprofloxacin 500 mg b.i.d. until 2003, after which time no antibacterial antibiotics were given routinely. Blood products were all from CMV seronegative donors. A policy of surveillance for pp65 Ab and pre-emptive therapy with ganciclovir was used when donor and/or recipient were CMV Ab positive. Routine monitoring for EBV viral load was not done. The acute GVHD (aGVHD) prophylaxis protocol included CsA orally or i.v. twice daily to maintain blood levels between 150 and 400 mmol/L. MTX was given at 15 mg/m 2 i.v. on day 1 and 10 mg/m 2 on days 3, 6 and 11. Folinic acid 5 mg i.v. or p.o. was started 24 h after each MTX dose and continued every 6 h until 12 h before the next dose. 15 In addition all patients were given rabbit antithymocyte globulin (Thymoglobulin, Genzyme, Cambridge, MA, USA) 4.5 mg/kg i.v. in divided doses over 3 days. Each dose was given as a continuous infusion over 4-8 h. To minimize reactions, the first dose was reduced to 0.5 mg/kg, the next two doses were 2 mg/kg and the final infusion was given on the day of transplant. Premedication included methylprednisolone 40 mg i.v. every 12 h for six doses and benadryl 50 mg i.v. before each dose of antithymocyte globulin.
If no aGVHD occurred CsA was tapered over 4-8 weeks with the intent to discontinue by 3-4 months from transplant.
Engraftment
Daily blood counts were done until discharge, BM aspirations at 3 months for surviving patients and thereafter as clinically indicated. Granulocyte engraftment was defined as a count of 40.5 Â 10 9 /L for 3 consecutive days. The platelet count needed to be above 20 Â 10 9 /L without transfusion for 7 days for engraftment to be documented. GVHD aGVHD was graded according to standard criteria. 16 Grading was performed by physicians at onset and during treatment with later confirmation and recording by data managers.
aGVHD was treated with prednisone or methylprednisolone initially while continuing CSA. First line therapy for steroid-resistant aGVHD was antithymocyte globulin 2 mg/kg every other day for 2-4 doses whereas CSA was withheld. Chronic GVHD (cGVHD) was treated with prednisone with or without CSA, with the introduction of other agents if response was incomplete.
Statistical analysis
Continuous data are presented as the median and range, and categorical data as counts and percents. For analysis of time to TRM, patients were right-censored at time of relapse and relapse was treated as a competing event, and vice versa. For analysis of onset of cGVHD, patients were right-censored at the time of death, donor lymphocyte infusion or second transplant. Death was considered a competing event for cGVHD. The clinical endpoints of relapse, TRM, disease-free survival (DFS) and OS are recorded at 3 years from SCT.
Competing-risks regression was used to identify factors associated with rates of relapse, TRM, relapse or death, mortality, aGVHD and cGVHD using the method of Fine and Gray. 17 Cox hazards regression was used for the same purpose for the outcomes of DFS and OS, as they have no competing events. Variables considered were patient age (per year), matched-related or alternative donor, CMVpositive recipient or donor, female-to-male transplant, cell source (BM or BC), disease risk, the use of TBI and the HCT-CI. Subhazard ratios (SHR) and hazard ratios (HR) as well as their associated 95% confidence intervals (CIs) were used as measures of strength of association and precision, respectively. Data analysis was performed using Stata statistical software version 11 (Stata Corp., College Station, TX, USA).
For all analyses P-values below 0.1 (Po0.100) are reported as trends, those below 0.05 (Po0.050) are referred to as statistically significant.
Results
Engraftment
Of patients with HCT-CI scores of 0 two died before day 21 without engraftment, a third was re-transplanted at day 50 for graft failure.. The remaining 114 evaluable patients engrafted granulocytes at a median of 16 days (range [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . Six patients with granulocyte recovery failed to have platelet engraftment, two because of relapse, three because of TRM between days 18 and 31 and one who was re-grafted on day 70 for graft failure. The remaining 108 patients had platelet recovery between days 0 and 54 (median 18).
Four patients with HCT-CI scores of X1 died without relapse on days 8-14 and two were re-transplanted for graft failure on days 21 and 42. The remaining 80 evaluable patients engrafted granulocytes at a median of 15 days (range [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . Six patients with granulocyte recovery failed to have platelet engraftment because of non-relapse death between days 29 and 64. The remaining 80 patients had platelet recovery between days 0 and 44 (median 19).
GVHD
For patients with HCT-CI scores of 0 and X1 the incidence of aGVHD grade II-IV was 20 vs 26%, aGVHD grade III-IV 9 vs 11% and cGVHD (at 2 years) 51 vs 41%, respectively. None of these differences are statistically significant.
The risk of developing aGVHD grade II-IV was related to whether it was an alternative or matched sibling donor (relative risk ¼ 1.77; 95% CI ¼ 0.99-3.18; P ¼ 0.056). This finding was confounded by the presence of comorbid conditions, however, HCT-CI scores of X1 alone were not associated with increased risk of aGVHD grade II-IV (relative risk ¼ 1.20; 95% CI ¼ 0.67-2.16; P ¼ 0.525). Absence of a matched-sibling donor was associated with a nearly threefold risk of aGVHD grade III-IV (relative risk ¼ 2.78; 95% CI ¼ 1.10-7.02; P ¼ 0.030). Adjustment for HCT-CI scores did not impact this result and was not associated with the outcome (relative risk ¼ 1.14; 95% CI ¼ 0.47-2.76; P ¼ 0.768).
The subhazard of aGVHD grade III-IV is not different between those with HCT-CI scores of 0 and X1 (SHR ¼ 1.15; 95% CI ¼ 0.47-2.79; P ¼ 0.764) with consideration for alternate donor type, which was associated with increased risk of aGVHD grade III-IV (SHR ¼ 3.04; 95% CI ¼ 1.21-7.62; P ¼ 0.018). The other covariates of patient age, TBI, CMV, female-to-male donor, cell source (BM or BC) and patient risk group were not found to be significant.
Factors associated with cGVHD (at 2 years) were male recipients of transplants from female donors (SHR ¼ 1.89; 95% CI ¼ 1.21-2.97; P ¼ 0.005), patient age (SHR ¼ 0.95; 95% CI ¼ 0.90-1.00; P ¼ 0.042), high-risk disease (SHR ¼ 1.63; 95% CI ¼ 1.04-2.56; P ¼ 0.032) and alternate donor (SHR ¼ 1.55; 95% CI ¼ 1.01-2.38; P ¼ 0.047). Table 2 gives the causes of non-relapse death. In patients with HCT-CI scores of 0 TRM was 15 and 19% at 1 and 5 years compared with 31% and 39% for patients with HCT-CI scores of X1 (P ¼ 0.003, Figure 1) . For all 207 patients TRM was 28% at 5 years, for 114 patients with AML and MDS the figure was 25%.
Transplant-related mortality
Both HCT-CI scores of X1 (SHR ¼ 2.29; 95% CI ¼ 1.29-4.08; P ¼ 0.005) and patient age (SHR ¼ 1.06; 95% CI ¼ 1.00-1.13; P ¼ 0.064) were associated with TRM.
Relapse
Incidence of relapse in patients with HCT-CI scores of 0 was 26% at 1 year and 36% at 5 years compared with 19 and 39% in those with scores of X1.
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HCT-CI scores of X1 were not associated with increased risk of relapse (SHR ¼ 1.12; 95% CI ¼ 0.67-1.88; P ¼ 0.662). However, the hazard was increased in patients with high-risk disease (SHR ¼ 1.98; 95% CI ¼ 1.09-3.62; P ¼ 0.026) and decreased in those with an alternate donor (SHR ¼ 0.53; 95% CI ¼ 0.29-0.94; P ¼ 0.031). Figure 2 shows DFS and OS for the two risk groups. For patients with HCT-CI scores of 0 and X1 OS at 1 and 5 years was 74 and 54% vs 56 and 39% (P ¼ 0.008), DFS was 68 and 49% vs 50 and 38% (P ¼ 0.03).
DFS and OS
OS was associated with HCT-CI scores of X1 (HR ¼ 2.00; 95% CI ¼ 1.33-3.01; P ¼ 0.001), disease risk group (HR ¼ 1.75; 95% CI ¼ 1.10-2.76; P ¼ 0.017) and patient age (HR ¼ 1.06; 95% CI ¼ 1.01-1.11; P ¼ 0.021).
DFS was influenced by the presence of HCT-CI scores of X1 (HR ¼ 1.92; 95% CI ¼ 1.29-2.85; P ¼ 0.001), disease risk group (HR ¼ 1.71; 95% CI ¼ 1.10-2.66; P ¼ 0.017) and patient age (HR ¼ 1.08; 95% CI ¼ 1.03-1.13; P ¼ 0.002).
In 48 AML patients in CR1 and CR2 receiving this protocol with TBI 27 (56%) had with HCT-CI scores of X1. At 5 years, DFS was 81% for those with scores of 0 and 54% for those with scores of X1 (P ¼ 0.04, Figure 3 ). (1) Encephalopathy (1) GVHD (5) Adult respiratory distress syndrome (3) Graft failure (1) GVHD (5) Veno-occlusive disease (1) Adult respiratory distress syndrome (2) Hemolysis ( and CR2.
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Discussion
The HCT-CI developed by Sorror et al. 1 provided an objective tool for evaluation of comorbidities in hematopoietic SCT (HSCT) and confirmation of the powerful influence of these pretransplant factors on outcome. 1 A subsequent collaboration between the Seattle and MD Anderson programs confirmed that this index had prognostic value across institutions for AML in CR1 and was more accurate than other comorbidity indices. 2 Other investigations, with some exceptions, have confirmed the value of this index in predicting outcome of SCT from different cell sources in a variety of hematologic malignancies. 10, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] The current report also confirms a powerful influence of comorbidities, as assessed by the HCT-CI, on TRM in older patients treated with the FLUBUP regimen. The analysis could not discriminate between patients with HCT-CI scores of 1-2 or X3, perhaps because of insufficient numbers. As with the above studies, data collection was retrospective, perhaps leading to some underestimation of comorbidities, but the conclusions are consistent.
The ability to collect large numbers of progenitor cells from peripheral blood and the introduction of powerful immunosuppressants such as fludarabine has led to the widespread use of NST and RIC regimens. The objective was to achieve engraftment without the toxicity of MA protocols and rely more on the graft-vs-malignancy effect to eradicate the underlying disease. It was thought that this would allow allogeneic HSCT to be used in older patients and/or those with comorbidities who could not tolerate MA regimens. Although numerous reports have confirmed the feasibility of this approach, the role of these regimens in contrast to fully MA conditioning remains controversial. As patient populations receiving NST and RIC regimens are usually heterogeneous with respect to many prognostic factors it is difficult to make direct comparisons of outcomes particularly without information on comorbidities. There is, however, evidence that these regimens in general do result in lower toxicity and early TRM than conventional MA protocols. 10, 24, [26] [27] [28] A review of over 4000 NST recipients by Banna et al. 4 showed an overall TRM at 1 year of 18%. 4 Although the two earlier studies by Sorror et al.
1,2 involved patients receiving NST and RIC regimens, they did not evaluate separately the influence of comorbidities on outcomes of patients given these treatments. 1, 2 Subsequent investigations have confirmed their significance in this context. 21, 23, 25, 26, 29 The relative contribution of regimen intensity and graftvs-malignancy varies according to disease. In AML, the most common indication for allo-SCT, there is compelling evidence that relapse increases as the regimen intensity decreases. [7] [8] [9] [10] 28, 30, 31 This effect is compensated for to some extent by the reduction in early TRM and so the DFS and OS may be similar. A recent study of patients with AML and MDS has in fact shown that TRM at 5 years may not in fact differ much between regimens.
32 TRM with MA, RIC and NST protocols was very similar at 34-37%, little different from our series of older patients with HCT-CI scores X1. Clearly the risk factors differed between the groups, in particular the patients receiving MA conditioning were younger. The choice of regimen for AML and MDS is complex as a balance has to be struck between risk of relapse with less intense regimens and TRM with MA protocols. We have shown that addition of 400 cGy to the FLUBUP regimen significantly reduces relapse without affecting TRM, resulting in a relatively well-tolerated regimen with antileukemic activity in AML equivalent to other MA regimens. 31 In our admittedly small cohort, patients with AML in CR1 and CR2 aged X50 years and with HCT-CI scores of 0 had a 5-year DFS after the FLUBUP/TBI regimen of 81% and even those with scores X1 had a DFS of 54%. Outside a clinical trial, it may therefore be reasonable to offer this regimen at least to all patients up to 66 years old. Our experience is consistent with other studies showing that MA regimens with improved tolerability can be used successfully in older patients with AML. 33 With the exception of AML no subgroup of patients was large enough for us to reach conclusions about the role of this regimen in other diseases. We can however conclude that age alone should not be a contraindication to using it. In older patients with or without comorbidities as measured by the HCT-CI, more experience, including comparative studies, is needed before conclusions can be drawn regarding the preferred approach in individual malignancies.
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